Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214642 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study for Patients With Advanced Cancer
A Phase 1 study of Advanced Cancer, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 2
- Study locations
NCT01214642: Completed Phase 1 study of Advanced Cancer, sponsored by Eli Lilly and Company.
NCT01214642 is a Phase 1 study of Advanced Cancer that has completed, run by Eli Lilly and Company. The registered enrollment target is 63 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (74% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01214642, a Phase 1 study of Advanced Cancer, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).
Primary Outcome
The recommended dose and schedule for Phase 2 studies is defined as the maximum tolerated dose (MTD). MTD is defined as the dose level at which no more than 2 dose limiting toxicities (DLTs), no more than 3 dose reductions (DR) or dose omissions (DO) and no more than 1 DLT plus 2 DR/DO occurred. DLT is defined as an adverse event (AE) occurring in Cycle 1 with the following criteria according to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0: An
Conditions Studied
Interventions
- DRUG pegfilgrastim
- DRUG LY2523355
Study Locations (2)
Tennessee
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Nashville
Texas
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2008-05 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
What the finished NCT01214642 record still lists
NCT01214642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which pegfilgrastim is the first listed.
NCT01214642 reports a single indexed study location in Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT01214642 about?
NCT01214642 is a clinical study titled "A Dose-Escalation Study for Patients With Advanced Cancer". This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).
What is the current status of trial NCT01214642?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2008-05. Estimated completion is 2012-06.
What conditions does trial NCT01214642 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT01214642?
The interventions under investigation include: pegfilgrastim (DRUG), LY2523355 (DRUG).
Who is sponsoring clinical trial NCT01214642?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01214642 being conducted?
This trial has 2 study locations across Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01214642's enrollment target sits among peer trials
63 77th of 122 higher than 46 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia